News
Multiple myeloma drug Blenrep backed for wider NHS use
The revitalisation of GSK's Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.
News
Beeline raises $300m for BMS drugs, and other biofinancings
Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.
News
Revolution rockets on strong pancreatic cancer data
Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib.
News
IDEAYA/Servier PKC drug aces uveal melanoma trial
Servier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.
News
AI could spare bowel cancer patients from unneeded treatment
An AI tool could identify colorectal cancer patients most likely to respond to bevacizumab, which was recently backed for NHS use.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
